Awards & recognitions.

Rosetta Omics has been awarded the Grand Prix Startup Santé 2026 by BFM Business. A recognition of our team, partners, investors and ecosystem, and of our mission: unlocking the full potential of precision medicine in oncology to better predict treatment response and improve outcomes for patients.

Chosen from 4,800+ applications across 108 countries, Rosetta Omics is now part of the world's largest community of hard tech startups solving the world's toughest challenges. We will be pitching at the Hello Tomorrow Summit in Amsterdam on 11–12 June 2026.

An expert program by Voisin Consulting Life Sciences supporting our regulatory pathway and go-to-market strategy, working with a top team of regulatory experts to bring our precision oncology solutions to patients, oncologists, hospitals and biopharma partners.

Recognition at the Saudi Biotechnology Accelerator achievement forum, held at the King Abdulaziz City for Science and Technology (KACST) in Riyadh, after two months of intense work in the venture readiness program. A step toward strategic, long-term partnership with major healthcare players in the Kingdom.

Digital certificate/badge issued by the Saudi Biotechnology Accelerator via Sertifier, marking the completion of the Biotechnology Venture Readiness Program 2025.

Rosetta Omics has been selected as a laureate of the France 2030 AI Pioneers program with MAP-AI: a Multiomics Analytics Platform with Artificial Intelligence for Precision Therapy. MAP-AI integrates spatial and multi-omics data with AI to predict patient treatment response, identify clinically actionable biomarkers, discover novel therapeutic targets and improve survival.

Rosetta Omics has been selected to join the Wilco One Program, accelerating our mission in precision oncology and AI-driven healthcare innovation alongside other outstanding startups.

Rosetta Omics' selection follows a productive exchange at the KSA Pavilion of the BIO International Convention in Boston. The program connects us with mentors, investors, KOLs and SFDA representatives, and culminates in a final showcase in Riyadh in December 2025. A strategic step in our expansion into the GCC and MENA regions.

9 months of personalised mentorship led by Pfizer in partnership with WILCO, alongside BioKortex, Doctoome, Emobot, Pictaderm and Primaa, to demonstrate how our AI-enabled multiomics platform supports anti-cancer drug developers in biomarker discovery, target validation and treatment-response prediction.

At the 6th edition of HTIDs by HealthTech For Care in Paris, Rosetta Omics won the 1st place 🥇 among 20 selected top European companies, validating our spatial multiomics + AI approach for precision oncology.

Out of more than 50 startup candidates led by ESCP Business School and ESCP Alumni, Rosetta Omics won the honorary innovation prize from Groupe BPCE, a recognition rooted in the ESCP community where Rosetta Omics was born.

The JEI status by the French State recognises Rosetta Omics' commitment to R&D in precision medicine, oncology, AI and multiomics. It also opens up attractive tax incentives for current and future investors.

Selected among the winners of the Bio Partnering Pass Challenge organised by Medicen Paris Region, Spartners by Servier and BioLabs France, joining a delegation of bright French startups at international partnering events.

Dr. Awad represents the pharma, biotech, medtech and diagnostics SMEs of Île-de-France in the executive office of Medicen, the global competitiveness cluster positioning Paris as a European leader in health innovation.

Out of 4,600 applications from 120 countries, Rosetta Omics was selected as a Deep Tech Pioneer, gaining year-round access to Hello Tomorrow's global community of investors and operators.

An ambitious program led by UM6P with STATION F and WILCO, helping us explore impactful collaborations with Moroccan and African hospitals, oncologists and investors to bring precision oncology to African patients.

A non-dilutive deeptech grant funding two POC studies in solid tumors, awarded after a rigorous due-diligence process. Part of the France 2030 Deeptech Plan.

Rosetta Omics joined Agoranov, the leading French incubator for deeptech and life sciences, to accelerate growth, access mentorship, and connect with the French innovation ecosystem.

Following four highly successful pitch sessions, Rosetta Omics was named the 3rd winner in the history of HTID pitch competitions.

Dr. Awad represents the pharma, biotech, medtech and diagnostics SMEs in the executive office of PSCC, accelerating innovation in oncology in France.

Rosetta Omics joined the OncoEntrepreneur program supported by PSCC and Cancer Campus, alongside 16 biotech, medtech and e-health projects benefiting from 20+ master classes.

Rosetta Omics joined the Blue Factory incubation program at ESCP Business School to connect with brilliant entrepreneurs and structure its early growth.